Article
HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.
Journal of acquired immune deficiency syndromes (1999) - 1 Apr 2013
Andreatta Kristen, Miller Michael D, White Kirsten L
Abstract excerpt
BACKGROUND: HIV-2 is susceptible to only a subset of approved antiretroviral drugs. A single tablet regimen containing the integrase strand transfer inhibitor elvitegravir (EVG) boosted by cobicistat plus the nucleoside reverse transcriptase (RT) inhibitors emtricitabine (FTC) and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) has potent activity against HIV-1 and may have utility against HIV-2. METHODS: HIV-2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.